Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myrto Samara

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
The American Journal of Psychiatry|May 26, 2017
Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy PredictorsStefan Leucht, Claudia Leucht, Maximilian Huhn, et al.
European Archives of Psychiatry and Clinical Neuroscience|April 28, 2026
Cannabidiol for the treatment of positive and negative symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysisAntonio Di Francesco, Pierfelice Cutrufelli, Cecilia Chiarenza, et al.
Annals of General Psychiatry|March 13, 2025
Physical illness in schizophrenia and the role of tolerability in antipsychotic selection: an expert consensus with a focus on cariprazineAlessandro Cuomo, Giovanni B Forleo, Taieb Ghodhbane, et al.
Lancet (London, England)|July 2, 2013
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisStefan Leucht, Andrea Cipriani, Loukia Spineli, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
The American Journal of Psychiatry|May 26, 2017
Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy PredictorsStefan Leucht, Claudia Leucht, Maximilian Huhn, et al.
European Archives of Psychiatry and Clinical Neuroscience|April 28, 2026
Cannabidiol for the treatment of positive and negative symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysisAntonio Di Francesco, Pierfelice Cutrufelli, Cecilia Chiarenza, et al.
Annals of General Psychiatry|March 13, 2025
Physical illness in schizophrenia and the role of tolerability in antipsychotic selection: an expert consensus with a focus on cariprazineAlessandro Cuomo, Giovanni B Forleo, Taieb Ghodhbane, et al.
Lancet (London, England)|July 2, 2013
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisStefan Leucht, Andrea Cipriani, Loukia Spineli, et al.
Pageof 6